https://www.live-feeds.com/feed/novartis-shares-fall-after-heart-drug-misses-target-in-late-stage-trialContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novartis-shares-fall-after-heart-drug-misses-target-in-late-stage-trialhttps://www.live-feeds.com/feed/novartis-shares-fall-after-heart-drug-misses-target-in-late-stage-trial#u64866Fri, 11 Sep 2026 07:46:19 +0000A major Novartis shareholder has demanded a board shake-up following recent clinical trial failures for the Swiss drugmaker. Novartis previously announced that its heart drug pelacarsen missed its primary goal in a large late-stage clinical trial, failing to reduce heart attacks, strokes, or cardiovascular deaths despite successfully lowering lipoprotein(a). This setback occurred alongside a missed primary endpoint for the muscle-wasting disorder drug del-desiran, putting pressure on company leadership and causing sharp share drops for partners Ionis Pharmaceuticals and Amgen.Why it mattersCar https://www.live-feeds.com/feed/novartis-shares-fall-after-heart-drug-misses-target-in-late-stage-trialhttps://www.live-feeds.com/feed/novartis-shares-fall-after-heart-drug-misses-target-in-late-stage-trial#u62911Wed, 09 Sep 2026 16:56:47 +0000Novartis shares fell between 13.5% and 14% after its heart drug pelacarsen failed a phase 3 trial. While the drug successfully lowered lipoprotein(a), a genetic risk factor, it did not reduce the occurrence of strokes, heart attacks, or cardiovascular deaths. This failure coincides with a miss on the primary endpoint for del-desiran, a muscle-wasting disorder drug linked to a 12 billion dollar deal. The combined setbacks have pressured Novartis leadership and triggered share price drops for partners Ionis Pharmaceuticals and Amgen.Why it mattersThe failure of pelacarsen creates uncertainty reg https://www.live-feeds.com/feed/novartis-shares-fall-after-heart-drug-misses-target-in-late-stage-trialhttps://www.live-feeds.com/feed/novartis-shares-fall-after-heart-drug-misses-target-in-late-stage-trial#u61893Tue, 08 Sep 2026 21:41:12 +0000Novartis shares fell 14% after its Lp(a) drug, pelacarsen, failed to lower cardiovascular risk in a phase 3 trial. The failure impacted partners and competitors, causing Ionis Pharmaceuticals shares to drop 13.1% to $50 and Amgen shares to fall 10%. This result raises questions about the viability of the emerging Lp(a) cholesterol drug class. The setback follows another late-stage study failure for a Novartis muscle-wasting disorder drug, del-desiran, increasing pressure on the company's pipeline and leadership.Why it mattersLp(a) drugs target a specific type of cholesterol to reduce hear